Annual report pursuant to Section 13 and 15(d)

INCOME TAXES

v2.4.1.9
INCOME TAXES
12 Months Ended
Dec. 31, 2014
INCOME TAXES [Abstract]  
INCOME TAXES
NOTE 12 - INCOME TAXES

Income tax expense differs from the statutory amounts as follows:

   
2014
   
2013
 
         
Income taxes at U.S. statutory rate
 
$
(9,105,000
)
 
$
1,513,000
 
Current year reserve
   
1,254,000
     
224,000
 
Expenses not deductible
   
7,851,000
     
(1,737,000
)
                 
Total tax expense
 
$
-
   
$
-
 

Deferred taxes are provided for the temporary differences between the financial reporting bases and the tax bases of our assets and liabilities. The temporary differences that give rise to deferred tax assets were as follows:
 
   
December 31,
 
   
2014
   
2013
 
Deferred tax assets
       
Net operating loss carryforwards
 
$
68,263,000
   
$
63,087,000
 
General business credit carryforwards
   
2,486,000
     
2,362,000
 
State credits
   
2,061,000
     
3,053,000
 
Property and equipment
   
-
     
-
 
Stock options
   
542,000
     
473,000
 
Derivatives
   
(92,000
)
   
(92,000
)
Deferred revenue
   
92,000
     
1,072,000
 
Intangible assets
   
464,000
     
418,000
 
Accrued interest
   
253,000
     
253,000
 
Other
 
231,000
     
231,000
 
Gross deferred tax assets
   
74,300,000
     
70,857,000
 
Valuation allowance
   
(74,300,000
)
   
(70,857,000
)
Net deferred taxes
 
$
-
   
$
-
 

At December 31, 2014, we had approximately $200,744,000 of net operating loss carryforwards and approximately $2,486,000 of general business credit carryforwards. These carryforwards expire as follows:
 
   
Net operating
loss carryforwards
   
General business
credit carryforwards
 
2013
 
$
-
   
$
-
 
2014
   
-
     
-
 
2015
   
-
     
-
 
2016
   
-
     
-
 
Thereafter
   
200,744,000
     
2,486,000
 
   
$
200,744,000
   
$
2,486,000
 

As a result of a merger on January 25, 1996, a change in control occurred for federal income tax purposes, which limits the utilization of pre-merger net operating loss carryforwards of approximately $3,100,000 to approximately $530,000 per year.

Additionally, we acquired MacroChem Corporation on February 25, 2009 and Somanta Pharmaceuticals, Inc. on January 4, 2008. Both corporations were loss companies at the time of the acquisition. Therefore, the net operating losses related to those acquisitions may be subject to annual limitations as provided by IRC Sec. 382.